|UNITED
          STATES
          SECURITIES AND EXCHANGE COMMISSION
          WASHINGTON, D.C. 20549 FORM. 10-QSB
        [ X ]	QUARTERLY REPORTS
          UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR
          THE QUARTERLY PERIOD ENDED December 31, 2000.
        OR
        [ ]	QUARTERLY REPORTS
          UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR
          THE TRANSITION PERIOD FROM ____________ TO ______________.
        Commission
          File No. 0-19844
        -----------
        PARACELSIAN,
          INC.
        ------------------------------------------------------
        (Exact
          name of small business issuer as specified in its charter)
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Delaware                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  | 16-1399565                                    
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ----------------------------------------------
|-----------                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  | --------------------                          
|(State
          or other jurisdiction of incorporation or organization)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  | (I.R.S.
          Employer Identification No.)
|222 Langmuir
          Laboratories, Cornell Technology Park, Ithaca, New York                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  | 14850                                         
|--------------------------------------------------------------------                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  | --------------------                          
|(Address
          of principal executive offices)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | Zip Code                                      
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  |                                               
|Issuer's
          telephone number: (607) 257-4224
          -----------------------------------------------------
        Check whether the issuer (1) filed all
          reports required to be filed by section 13 or 15(d) of the Securities
          Exchange Act during the past 12 months (or for such shorter period that
          the registrant was required to file such reports, and (2) has been subject
          to such filing requirements for the past 90 days.
        
        Yes [X] No [ ]
        
        There were 23,490,849 shares of Common
          Stock outstanding at February 1, 2001

|(Page
          1)                                                                                                                                                                       
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Paracelsian,
          Inc. and Subsidiary
        Index                                                                                                                                 
|                                                                                                                                                                                         
|PART I.  FINANCIAL
          INFORMATION                                                                                                                                                
|                                                                                                                                                                                         
|Item 1.	Financial
          Statements                                                                                                                                                   
|                                                                                                                                                                                         
|Consolidated Balance Sheet
          as of December 31, 2000 (Unaudited)                                                                                                                 
|                                                                                                                                                                                         
|Consolidated Statements
          of Operations for the three months ended December 31, 2000 and 1999
          and the cumulative period from inception to December 31, 2000 (Unaudited)
|                                                                                                                                                                                         
|Consolidated Statements
          of Cash Flows for the three months ended December 31, 2000 and 1999
          and the cumulative period from inception to December 31, 2000 (Unaudited)
|                                                                                                                                                                                         
|Notes to Consolidated Financial Statements (Unaudited)                                                                                                                                   
|                                                                                                                                                                                         
|Item. 2 Managements Discussion and Analysis
          of Financial Condition and Results of Operations                                                                                 
|                                                                                                                                                                                         
|PART II  OTHER INFORMATION                                                                                                                                                              
|                                                                                                                                                                                         
|Item 1 Legal Proceedings                                                                                                                                                                
|                                                                                                                                                                                         
|Item 6 Exhibits and Reports of Form 8-K                                                                                                                                                 
|                                                                                                                                                                                         
|Signatures                                                                                                                                                                               

|                                                                                                                                                          |                                                                       |         |                   
|--------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------- | ------- | ------------------
|                                                                                                                                                          |                                                                       |         | (Page
          2)
|Paracelsian, Inc. and Subsidiary
          (A Development Stage Company)
            Consolidated Balance Sheet
            December 31, 2000 (Unaudited)
|                                                                                                                                                          |                                                                       |         |                   
|                                                                                                                                                          | Assets                                                                |         |                   
|Current Assets:                                                                                                                                           |                                                                       |        
|                                                                                                                                                          | Cash and cash equivalents                                             | $       | 35,027            
|                                                                                                                                                          | Inventory                                                             |         | -                 
|                                                                                                                                                          | Prepaid expenses                                                      |         | 48,271            
|                                                                                                                                                          | Other current assets                                                  |         | 11,961            
|                                                                                                                                                          | Total
          current assets                                        |         | 95,259            
|                                                                                                                                                          |                                                                       |         |                   
|Equipment, net                                                                                                                                            |                                                                       | 124,658
|Interest
        Receivable                                                                                                                               |                                                                       | 36,698 
|Note
        Receivable                                                                                                                                   |                                                                       | 148,750
|Other Assets:                                                                                                                                             |                                                                       |        
|                                                                                                                                                          | Patents and trademarks,
          net                                 |         | 209,079           
|                                                                                                                                                          |                                                                       |         | 519,185           
|                                                                                                                                                          | Liabilities
          and Stockholders Equity (Deficit)              | $       | 614,444           
|Current Liabilities:                                                                                                                                      |                                                                       |        
|                                                                                                                                                          | Accounts payable                                                      | $       | 380,715           
|                                                                                                                                                          | Accrued expenses                                                      |         | 504,113           
|                                                                                                                                                          | Current portion of
          capital lease obligation                 |         | 3,045             
|                                                                                                                                                          | Current portion of
          notes payable                            |         | 47,970            
|                                                                                                                                                          | Advances
        from related party                                   |         | 191,877           
|                                                                                                                                                          |                                                                       |         |                   
|                                                                                                                                                          | Total
          current liabilities                                   |         | 1,127,720         
|                                                                                                                                                          |                                                                       |         |                   
|Long-term Liabilities:                                                                                                                                    |                                                                       |        
|                                                                                                                                                          | Long-term portion
          of capital lease obligation               |         | 1,264             
|                                                                                                                                                          | Long-term
        portion of notes payable                            |         | 8,015             
|                                                                                                                                                          | Total
          current and long-term liabilities                     |         | 1,136,999         
|                                                                                                                                                          |                                                                       |         |                   
|Stockholders Equity
          (Deficit)                                                                                                                  |                                                                       |        
|                                                                                                                                                          | Common Stock, $.01
          par value; 35,000,000 shares authorized; |         |                   
|                                                                                                                                                          | 23,490,849
        shares outstanding                                 |         | 234,904           
|                                                                                                                                                          | Additional
        paid-in-capital                                    |         | 25,404,381        
|                                                                                                                                                          | Deficit
        accumulated during the development stage              |         | (24,819,325)      
|                                                                                                                                                          | Treasury
        stock, at cost; 265,478 shares                       |         | (1,342,515)       
|                                                                                                                                                          | Total
        stockholders' equity (deficit)                          |         | (522,555)         
|                                                                                                                                                          | $                                                                     | 614,444
|See accompanying
          notes to consolidated financial statements.                                                                                    |                                                                       |        

|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      | (Page
          3)                                                            
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------- | ---------------------------------------------------- | ------------------------------------------------------------------------------
|                                                                                                                                                                                                                                                                                  
|Paracelsian, Inc. and Subsidiary
          (A Development Stage Company)
            Consolidated Statements of Operations
            For the three months ended December 31, 2000 and 1999,
            And the cumulative period from inception to December 31, 2000(Unaudited)
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   |                                                                                   | Three
          Months Ended 
          December 31, | Cumulative
          Period
          from Inception to
          December 31,
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|Revenues                                                                                                                                                                                                                                                                           |                                                                                   | 2000                                                 | 1999                                                                          
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Marketing rights                                                                  | $                                                    | 63,255                                                                        
|                                                                                                                                                                                                                                                                                   | Products                                                                          |                                                      | 4,198                                                                         
|                                                                                                                                                                                                                                                                                   | Product testing                                                                   |                                                      | -                                                                             
|                                                                                                                                                                                                                                                                                   | Product royalties                                                                 |                                                      | -                                                                             
|                                                                                                                                                                                                                                                                                   | Subscription revenue                                                              |                                                      | -                                                                             
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Total
          Revenues                                                          |                                                      | 67,453                                                                        
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|Operating expenses:                                                                                                                                                                                                                                                                |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Research and product
          engineering                                        |                                                      | 122,945                                                                       
|                                                                                                                                                                                                                                                                                   | General and administrative                                                        |                                                      | 257,646                                                                       
|                                                                                                                                                                                                                                                                                   | Product launch costs                                                              |                                                      | -                                                                             
|                                                                                                                                                                                                                                                                                   | Cost of products sold                                                             |                                                      | 1,395                                                                         
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Total
          operating expenses                                                |                                                      | 381,986                                                                       
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Loss from operations
          during the development stage                       | $                                                    | (314,533)                                                                     
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|Interest income (expenses),
          net                                                                                                                                                                                                                                          |                                                                                   | (186)                                                | 16,312                                                                        
|Gain on sale of assets                                                                                                                                                                                                                                                             |                                                                                   | -                                                    | -                                                                             
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Net loss during the
          development stage                                   |                                                      | (314,719)                                                                     
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Net loss per weighted
          average share of common stock - basic and diluted | $                                                    | (0.01)                                                                        
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|                                                                                                                                                                                                                                                                                   | Weighted
        average number of shares outstanding - basic and diluted         |                                                      | 22,060,316                                                                    
|                                                                                                                                                                                                                                                                                   |                                                                                   |                                                      |                                                                               
|See
        accompanying notes to consolidated financial statements                                                                                                                                                                                                               
|(Page
          4)                                                                                                                                                                                                                                                                

|                                                                                                                                                                                                                                                                            
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Paracelsian,
          Inc. and Subsidiary(A Development Stage Company) 
          Consolidated Statements of Cash Flows
          For the three months ended December 31, 2000 and 1999,
          And the cumulative period from inceptionto December 31, 2000 (Unaudited)
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|Cash flows
        from operating activities:                                                                                                                                                                                                                               
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|Cash flows
        from investing activities:                                                                                                                                                                                                                               
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                            

|Cash flows
        from financing activities:                                 |                                                                                             |           |                                                   |        
|----------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------- | --------- | ------------------------------------------------- | -------
|                                                                              | Sale of common
        stock, initial public offering, net of costs                         |           | -                                                 | -      
|                                                                              | Sale of common
        and preferred stock, net of costs                                    |           | -                                                 | -      
|                                                                              | Proceeds from
        the sale of common stock                                              |           | -                                                 | -      
|                                                                              | Proceeds from
        the exercise of warrants                                              |           | -                                                 | -      
|                                                                              | Proceeds from
        the exercise of options                                               |           | -                                                 | -      
|                                                                              | Termination
        of warrants                                                             |           |                                                   |        
|                                                                              | Purchase of
        treasury stock                                                          |           | -                                                 | -      
|                                                                              | Cost of warrant
        dividend                                                            |           | -                                                 | -      
|                                                                              | Increase in capital lease obligation and notes
        payable                              |           | -                                                 | -      
|                                                                              | Payment on capital lease obligation                                                         |           | (4,240)                                           | (7,515)
|                                                                              | Proceeds from advances from related party                                                   |           | -                                                 | 220,638
|                                                                              | Payments on advances from related party                                                     |           | -                                                 | -      
|                                                                              | (Decrease) increase in notes payable                                                        |           | 14,194                                            | -      
|                                                                              |                                                                                             |           |                                                   |        
|                                                                              |                                                                                             |           | Net cash
        provided by financing activities |        
|                                                                              |                                                                                             |           |                                                   |        
|Net increase
        (decrease) in cash and cash equivalents                  | $                                                                                           | (192,096) | (64,940)                                          | 35,027 
|Cash and cash
        equivalents, beginning of period                        |                                                                                             | 227,123   | 72,754                                            | -      
|                                                                              |                                                                                             |           |                                                   |        
|Cash and cash
        equivalents, end of period                              |                                                                                             | 35,027    | 7,814                                             | 35,027 
|                                                                              |                                                                                             |           |                                                   |        
|                                                                              |                                                                                             |           |                                                   |        
|Supplemental
        disclosures:                                             |                                                                                             |           |                                                   |        
|                                                                              | Cash paid during
        the period for interest                                            | $         | 11,174                                            | 1,585  
|                                                                              |                                                                                             |           |                                                   |        
|Supplemental
        disclosure of non-cash investing & financing activities: |                                                                                             |           |                                                   |        
|                                                                              | Fair value
        of assets acquired, net of cash acquired                                 | $         | -                                                 | -      
|                                                                              | Less 
        liabilities assumed                                                          |           | -                                                 | -      
|                                                                              | Less 
        issuance of common stock                                                     |           | -                                                 | -      
|                                                                              | Net cash paid                                                                               |           | -                                                 | -      
|                                                                              | Warrant dividend                                                                            |           |                                                   |        
|                                                                              | Issuance of
        common stock/warrants for services and to reduce short-term liabilities |           | -                                                 | -      
|                                                                              | Purchase of
        equipment                                                               |           | -                                                 | -      
|                                                                              | Issuance of
        common stock for licensing and Technology rights                        |           | -                                                 | -      
|                                                                              |                                                                                             | $         | -                                                 | -      
|See accompanying
        notes to consolidated financial statements          
|(Page
          6)                                                           

|Paracelsian,
          Inc. and Subsidiary(A Development
          Stage Company)
        NOTES
          TO CONSOLIDATED FINANCIAL STATEMENTS 
          December 31, 2000
        (Unaudited)
        1.	BASIS OF PRESENTATION:
        The
          consolidated financial statements included herein have been prepared
          in accordance with generally accepted accounting principles without
          audit, pursuant to the rules and regulations of the Securities and Exchange
          Commission applicable to quarterly reporting on Form 10-QSB and reflect,
          in the opinion of the Company, all adjustments necessary to present
          fairly the financial position and results of operations for Paracelsian,
          Inc. and its consolidated subsidiary. All such adjustments are of a
          normal and recurring nature. Certain information and footnote disclosures
          normally included in financial statements, prepared in accordance with
          generally accepted accounting principles, have been condensed or omitted
          as permitted by such regulations. These consolidated financial statements
          and related notes should be read in conjunction with the consolidated
          financial statements and related notes included in the Companys
          Annual Report on Form 10-KSB for the fiscal year ended September 30,
          2000.
        2. 	ORGANIZATION,
          BUSINESS, AND RISK FACTORS:
        Organization and
          Business
        Paracelsian is a development
          stage company, which develops and applies bioassays to monitor environmental
          toxins, to determine the quality of herbal products, and to identify
          therapeutic compounds from herbal sources (www.paracelsian.com).
        The Company has developed
          a highly sensitive, user friendly, cost effective testing system for
          the detection and quantification of highly toxic environmental chemicals
          generally known as dioxin and dioxin-like compounds. It is called the
          Ah-IMMUNOASSAY® Kit (AH-1 Method).
        Since the discovery
          of the dioxin compounds, during the late 1950s, extensive research
          has been undertaken into their chemical and biological properties. And
          as more information becomes available, it is now clear that the original
          and narrowly defined group of dioxins is becoming more expansive
          to include many other highly toxic, chemically similar compounds.
        Dioxin, although singular
          in name, is actually comprised of at least 17 chemical variants or congeners
          of a larger dioxin family. These chemicals are highly toxic, with the
          most active congener (TCDD) being the most toxic chemical ever discovered.
          The number of chemicals with dioxin-like activity is even much larger
          still than the 17 original polychlorodibenzo-p-dioxin (PCDD) families,
          such as the polychlorodibenzofurans (PCDF), the polychlorinated biphenyls
          (PCBs), the polybrominated biphenyls (PBBs), the polycyclic aromatic
          hydrocarbons (PAHs), the heterocyclic amines (HAs), among others.
        Probably no other group
          of chemicals has invoked more public health concern and received more
          media attention than these dioxin and dioxin-like substances, both because
          of their widespread distribution and their capability for serious toxicity
          (e.g., cancer, birth defects, diabetes, hormone disruption, immunologic
          dysfunction, etc.). The Environmental Protection Agency (EPA) of the
          United States has concluded, for example, that more than 100 f these
          dioxins and dioxin-like chemicals are likely human carcinogens.
        Waste incineration
          is a major source of these chemicals. Paper mill bleaching and varied
          industrial syntheses also add significant amounts to the environment.
          Following release into the air, perhaps also into waste water or sludge,
          these chemicals then settle on plant material, soil, and water where
          they are likely to persist for very long periods of time. As a consequence,
          they tend to accumulate either onto particulate matter (such as found
          at the bottom of bodies of water), or into body fat reservoirs of animals
          and fishes which feed on the plants. And because of their stability
          and persistence, these chemicals accumulate to relatively high levels
          in animal based foods.
        (Page
          7)
        Investigating the distribution
          and toxicities of these chemicals has been challenging, both because
          of the ever-growing number of chemicals with dioxin-like activity and
          the difficulty of predicting toxicities. Because of these complexities,
          analysis of these chemicals has been very expensive, with the results
          being difficult to interpret.
        More recently, simpler
          analytical methods have been developed, such as the AH-1 Method, based
          on the use of biologically based concepts. Dioxins and dioxin-like chemicals
          (also called ligands), enter the cell and bind to a protein in the cytoplasm
          called Ah receptor (AhR), thus giving a ligand-AhR complex. This complex,
          by dropping and adding some smaller proteins (e.g., AhR translocator
          or ARNT, hsp-90 protein) is said to be transformed, thus
          enabling it to enter the nucleus to bind to a specific dioxin
          receptor element (or enhancer) (DRE) of DNA. This interaction
          with DNA occurs upstream of genes which then are activated
          to produce certain enzymes, some of which are highly correlated with
          the subsequent toxicity.
        The AH-I Method takes
          advantage of these facts. It is generally acknowledged, for example,
          that AhR binding appears to be essential for the development of toxicity
          by these chemicals. It is as if ligand binding of AhR is the main traffic
          intersection through which these chemicals pass on their way to produce
          their respective toxicities.
        In the AH-I Method,
          where an excess of AhR protein is provided, the amount of AhR-ligand
          complex that transforms is dependent on the amount of dioxin ligand
          present in the sample being assayed. The amount of the transformed complex
          is detected by using an antibody specific for the Ah-I protein component
          of the complex, thus giving the Immunoassay name to the
          method. (For the scientifically minded reader, there really are two
          antibodies: the first interacts with the ARNT protein in the complex
          while the second, containing an enzyme that catalyzes the formation
          of the color reaction, binds to the first antibody. The color being
          produced in the reaction shows how much of the complex is present.).
        Dioxin is a toxic chemical
          group of widespread public health concern, and more information is needed,
          especially on the distribution of this material in the environment.
          More survey data are needed not only to identify potential hot
          spots but also to allay unwarranted concerns. Until now, such
          survey work has been prohibitively expensive, but with the introduction
          of simpler and much more cost effective bioassay methods, such as the
          AH-1 Method, it is now possible to gather far more information in order
          to make wiser decisions.
        The herbal supplement
          market presents the opportunity to commercialize a quality assurance
          program that identifies the bioactivity present in herbal products,
          which are complex mixtures of substances. This product is a significant
          advance versus current practices for verifying the quality and the bioactivity
          of herbal products. This is the Companys BioFIT Quality
          Assurance Certification Program.
        Typically, the Company
          will investigate the effect of a compound or mixture of compounds on
          a disease (such as cancer) or a symptom (such as depression). The Company
          scientists conduct in depth research of the scientific literature and
          review the results of successful clinical trials to establish the best
          scientific explanation for the positive results seen in such trials.
          Based on their review, they identify the biological mechanism which,
          if activated, would best explain the positive clinical results. By defining
          such mechanisms of action associated with a wide variety of biological
          effects the Company scientists can then test a wide variety of natural
          materials in "in vitro" models which demonstrate these effects
          for the purpose of either discovering or confirming these biological
          activities. Such discovery or confirmation provides the Company with
          the basis for its BioFIT Program.
        The Company is continuing
          to work with its Chinese colleagues, during the appropriate market conditions,
          to expand the scope of the BioFIT program to the rest of the world.
        The Company is engaged
          in an internet-based health exchange between the US and China and currently
          maintains the website www.newcenturynutrition.com. The Company has excellent
          relations with recognized health authorities and organizations within
          the Peoples Republic of China. This website serves to provide
          a forum for the exchange of nutrition, health and related information.
          At its core is the New Century Nutrition website where renowned researchers,
          teachers and physicians from both countries can discuss their philosophies,
          research findings and health advice. Other components of the site include
          an herbal resource center featuring herbal databases from China, a nutrition
          resource center featuring healthy recipes and a technology center featuring
          the Ah-IMMUNOASSAY® Kit and the BioFIT Program. Our goal is
          to combine the best of Chinese medical practice with the best of Western
          practice creating new opportunities for information on health and disease
          prevention.
        (Page
          8)
        Development Stage
          Company and Risk Factors
        The Company is considered
          to be a development stage company as defined in Statement of Financial
          Accounting Standards No. 7, "Accounting and Reporting by Development
          Stage Enterprises." Since inception, the Company has been primarily
          engaged in research, product engineering and raising capital.
        
        The
          Company, as a development stage enterprise, has yet to generate significant
          revenues and has no assurance of substantial future revenues. The Company
          is subject to a number of risks that may affect its ability to become
          an operating enterprise or impact its ability to remain in existence,
          including risks related to successful development and marketing of its
          products, patent protection of proprietary technology, government regulation,
          competition from substitute products (including technologies that may
          not yet have been developed), dependence on key employees and the need
          to obtain additional funds that may not be available to it.
        
        As shown in the accompanying
          financial statements, the Company incurred a net loss of approximately
          $315,000 for the three months ended December 31, 2000 and had a working
          capital deficit of approximately $1,032,000 at December 31, 2000. Operating
          expenses decreased by $71,000(16%) as a result of decreases in a variety
          of expense categories, as part of the company's continual program to
          control and cut costs. Management believes that revenues from the sale
          of Ah-IMMUNOASSAY® Kits will accelerate throughout the coming year
          and that the Company will achieve positive cash flow from operations
          during 2001. Until such revenues are realized on a sustained basis,
          the Company will require additional capital to meet its obligations
          and continue operations.
        ITEM
          2. Managements Discussion and Analysis of Financial Condition
          and Results of Operations
          Three months ended December 31, 2000 as compared to the
          Three months ended December 31, 1999
        As a development stage
          enterprise, the Company, since inception, has been primarily engaged
          in research, product engineering, and capital formation. As such, the
          Company has not generated significant revenues to date on a recurring
          basis.
        The Company signed
          a final Licensing Agreement on January 21, 2000 with Kubota Corporation
          for the sale of Paracelsians Ah-IMMUNOASSAY® in the Japanese
          market and began manufacturing and selling kits to Kubota. This 'bioassay'
          based kit is rugged, user-friendly, portable, analytically sensitive,
          and low cost when compared with existing methodology. The agreement
          with Kubota will provide revenues from the sale of kits and royalties.
        On June 15, 2000 The
          Company announced that in accordance with the License Agreement, Kubota
          agreed to pay the $150,000 License Fee. This payment signifies Kubota's
          acceptance of the Ah-IMMUNOASSAY® Kit. Kubota and Paracelsian will
          now focus their efforts to market, sell and distribute the kit throughout
          Japan. On June 17, 2000 Kubota placed an initial order for 120 Ah-IMMUNOASSAY®
          Kits, and have placed monthly orders since June 2000.
        On November 2, 2000
          the EPA held an open meeting for public comments on the Dioxin Reassessment
          Report. Approximately 50 people from around the US were scheduled to
          present their comments to the Science Advisory Board Dioxin Reassessment
          Review Committee. Dr. T Colin Campbell, President & CEO of Paracelsian,
          reported to the committee his concerns about including in the report
          all of the dioxin and dioxin-like chemicals because of their capability
          for serious toxicity.
        (Page
          9)
        On December 7, 2000
          the Company entered into a Strategic Partnership Agreement with Triangle
          Laboratories, Inc., based in the Research Triangle Park in North Carolina.
          Triangle Laboratories is a recognized world leader in High Resolution
          Mass Spectrometry and dioxin testing. They were formed in 1984, and
          are still led by the founding scientists. Triangle provides a wide range
          of testing services to a broad customer base, specializing in the most
          demanding testing, such as dioxins and related compounds. The Agreement
          contemplates a unified system wherein the Companys AH-1 Method
          can be used by customers to screen large numbers of samples in a user-friendly
          manner and on a cost effective basis. Samples that are positive can
          then be assessed with the Triangle high-resolution gas chromatography/high
          resolution mass spectrometry assay system at the highest possible level
          of accuracy. The Partnership provides the basis for a more comprehensive
          agreement between the parties for the development and worldwide co-marketing
          of the multi-tiered testing system. The Companies specifically anticipate
          collaboration to make their combined capabilities available in the emerging
          Asian environmental markets, including China and Vietnam.
        The Company is projecting
          revenues from the sale of Ah-IMMUNOASSAY® Kits and testing services
          to be in excess of $1,000,000(unaudited), for the year 2001. On January
          18, 2001 the Company announced that Ernest A. Knesel agreed to join
          the Companys Sales and Marketing team. Mr. Knesel brings with
          him a long history of entrepreneurial involvement. He is best known
          as a founder of Biomedical Reference Laboratories, Inc. and Roche Biomedical
          Laboratories, Inc. Mr. Knesel joins NoriYoshi Inoue, Andrew Jolin and
          Dr. Thomas Knudsen, Paracelsians Director  Science Program
          on the team. Mr. Inoue and Mr. Jolin have been largely responsible for
          the Companys expanding relationship with Kubota Corporation of
          Japan, for generating additional sales and key contacts. Mr. Knesel
          will lead the efforts of this team to implement an aggressive strategy
          for generating additional revenue from the sale of Ah-IMMUNOASSAY®
          kits and testing services. Also participating on the team is Dr. J.
          Ronald Hass, President and CEO of Triangle Laboratories. Led by Dr.
          Hass, Triangle Laboratories has agreed to collaborate with the Company
          in the development of a presentation that joins the Companys Ah-IMMUNOASSAY®
          with the high resolution gas chromatography/high resolution mass spectrometry
          testing capability of Triangle Laboratories. Now that the Company has
          developed Ah-IMMUNOASSAY® into a very competitive and marketable
          product, this team has begun an aggressive and focused international
          rollout of this product, working towards developing a sustainable stream
          of revenues.
        The
          Ah-IMMUNOASSAY® Kits are continuing to be sold to the Kubota Corporation
          for the sale and distribution of the Ah-IMMUNOASSAY® in Japan. Kits
          have also been sold to Cypress Diagnostics in Belgium for the testing
          of animal feed. The University of Liege in Belgium has purchased kits
          for animal serum and tissue screening. SGS Agrilab in Antwerp, Belgium
          is the worlds largest inspection organization with 340 laboratories
          worldwide. SGS is waiting for the University of Liege screening results,
          and predicts a large market in Belgium. The Danish and Veterinary and
          Food Administration have purchased kits for the testing of fish, milk
          and fat. MCS Diagnostics is testing our kit for use in the German milk
          program. Dynex Technologies is using the kit for animal feed, food and
          environmental samples in the Czech and Slovak Republics. KNJ Engineering
          is using the kit with one of their customers, LG Chemical of Korea.
          KNJ sells dioxin-sampling equipment to incinerators and other applications
          in Korea. The Company has also begun discussions with Marubeni for exclusive
          distribution in Korea. Solutia has purchased the kit for testing organic
          material, and Scientific Supply Company purchased the kit for soil,
          milk powder and feed samples. Sales have also been made to Bristol Myers
          Squibb and Lockheed Martin. In February 2001, the Company will be meeting
          with the Vietnamese Ministry of Science, Technology and Environment
          (MOSTE) to discuss utilizing the Companys kits to screen the large
          number of soil, food and other samples that have shown high residual
          dioxin levels in Vietnam because of Agent Orange. Just recently Company
          representatives initiated discussions for sales of the Kit with two
          large corporations  Kodak and General Electric.
        Additionally, the Company
          has a note receivable outstanding, including accrued interest, with
          a face amount of $386,853($175,603 net of allowance). The Company is
          continuing its efforts to collect the entire amount of this receivable.
          The Company also has an inventory of Andrographis paniculata that it
          is attempting to sell through its Internet sites (www.newcenturynutrition.com
          and www.paracelsian.com). Andrographis is an annual plant that
          grows in much of Asia. Modern research has examined the effect of Andrographis
          on various viral infections and general immunological functions, and
          the research has indicated very promising results. Because this inventory
          has been slow moving, the Company has written it off completely. However,
          the Company will continue with its efforts to sell this inventory. If
          it is successful in its efforts, the retail value could approximate
          $400,000.
        (Page
          10)
        The Companys
          plan is to continue to advance the Ah-IMMUNOASSAY® technology so
          as to be the premier screening and monitoring methodology within the
          worldwide marketplace. To fund certain of its continual development
          expenses the Company, in January 2001, received an initial approval
          for a grant from the New York State Energy Research and Development
          Authority which could result in funding up to $180,000(unaudited). In
          addition, Kubota Corporation has indicated a willingness to contribute
          $150,000(unaudited) to the Company for further enhancements to the Ah-IMMUNOASSAY®.
        Management is also
          aggressively seeking an investment of at least $1,000,000 to strengthen
          its working capital position, and active discussions with a number of
          interested parties are continuing. Current monthly cash requirements
          in order to sustain meaningful operations are approximately $100,000,
          and management fully expects to meet its financial obligations as described
          above.
        The actions described
          above represent the Companys plans to generate cash flow, thereby
          enabling the Company to continue to operate as a going concern. There
          is no assurance that these efforts will be successful.
        Results of Operations
        
        The Companys
          net loss for the first quarter of fiscal 2001 was approximately $315,000
          compared to $453,000 in the first quarter of fiscal 2000. Revenues for
          the three-month period were $67,000 in 2000 as compared to $77,000 in
          1999. Operating expenses for the three-month period were approximately
          $382,000 compared to $453,000 for the first fiscal quarter of the prior
          year. The decrease of $71,000 is due to a decrease in a number of expense
          categories, as part of the company's continual program to control and
          cut costs. The management team is continuing to operate with modest
          staff levels and has been focusing on continuing to optimize the use
          of its resources, increasing its customer base and generating revenues.
        Liquidity &
          Capital Resources
        As of December 31,
          2000, the Company had cash of $35,000 and a net working capital deficit
          of $1,032,000. Management believes that it can continue to raise additional
          capital through private placements, to support its operations until
          such time as the revenue stream is sufficient to realize positive cash
          flow in 2001. Management believes that the additional financing coupled
          with its expected revenues from the Ah-IMMUNOASSAY® and the sale
          of its inventory of Andrographolide will enable the Company to further
          improve its operating efficiency and to continue its operations into
          the future.
        Management and The
          Board
        The management of the
          Company will be focusing their efforts on bringing the Company products
          and services to market in a timely manner, producing ongoing revenues
          and controlling expenses.
        Short Term Advances
        BioSignia, Inc., the
          Companys largest shareholder, has advanced interim funds to the
          Company for working capital purposes. The Company agreed to repay the
          funds, together with interest at an annual rate of 10%, at the earlier
          of 30 days from the date of the advance or the receipt by the Company
          of proceeds from the sale of stock. On June 19, 2000, the Board of Directors
          agreed to accept BioSignia's offer to convert $500,000 of debt into
          common stock of Paracelsian at $.40 per share. Through December 31,
          2000, the principal portion of advances from BioSignia aggregated $191,877.
        Patents
        The United State Patent
          & Trademark Office in October 2000 issued to the Company Patent
          # 6,127,136 for the detection of dioxin-like compounds. This patent
          relates to new, approved and user-friendly methods of detecting dioxin-like
          compounds by detecting the transformed Ah receptor. This patent gives
          the Company the protection it needs to continue to strengthen its presence
          in the worldwide dioxin detection marketplace. In November 2000 the
          United States Patent & Trademark Office issued to the Company Patent
          # 6,140,063, in vitro screening assay for the identification of compounds
          that inhibit destruction of cells due to viral infection. This patent
          represents a potential new screening pathway for anti-viral compounds.
        (Page
          11)
        Forward Looking
          Statements
        Certain statements
          in this Form 10-Q "Management's Discussion and Analysis of Financial
          Condition and Results of Operations" constitute "forward looking statements"
          within the meaning of the Private Securities Litigation Reform act of
          1995. Such forward looking statements involve known and unknown risks,
          uncertainties and other factors which may cause the actual results,
          performance or achievements of the Company to be materially different
          from any future results, performance or achievements expressed or implied
          by such forward looking statements. Such factors include, among others,
          the following: success of operating initiative, advertising and promotional
          efforts, acceptance of new product offerings, availability, changes
          in business strategy or development plan, availability and terms of
          capital, labor and employee benefit costs, and other factors specifically
          referred to in this 10-Q.
        PART II		OTHER
          INFORMATION
        Item 1.		Legal
          Proceedings
        Hadyk, et al. V.
          John G. Babish, et al.
        On February 14, 2001
          the Hadyk, et al. V. John G. Babish, et al. case that was commenced
          in the New York State Supreme Court (Onondaga County) in June 1993 by
          certain persons against the Company was dismissed.
        This case was commenced
          by certain person, individually and doing business as In Vitro Bioanalytic
          Systems, against the Company, Dr. John G. Babish, a former officer and
          director of the Company, and Edward Heslop, a founding shareholder of
          the Company, primarily as an action for money damages and injunctive
          relief against the Company for alleged misappropriation of proprietary
          information and unfair competition. The plaintiffs alleged, among other
          things, that in 1990, prior to the Companys incorporation, a partnership
          had been formed with Messrs. Babish and Heslop to commercialize products
          that the Company was developing. Damages, an accounting and an injunction
          were being sought against the Company. By decision dated September 14,
          1994, the Court dismissed certain of the plaintiffs claims against
          the Company while permitting a claim alleging unfair competition to
          proceed. Discovery had been temporarily stayed pending resolution of
          a motion for summary judgment brought by certain of the Companys
          co-defendants. That motion was successfully and fully resolved, and
          the Court, on February 14, 2001, ruled in favor of the Company. The
          Court not only exonerated the Company of any wrongdoing, but also agreed
          with the plaintiffs fundamental premise that they had a property
          interest in the technology at issue in this case.
        Item 6(a)	       Exhibits
        None
        Item 6(b)        Reports
          on Form 8-K
        None
        (Page
          12)
        SIGNATURES
        In
          accordance with Section 13 or 15(d) of the Securities and Exchange Act,
          the registrant caused this report to be signed on its behalf by the
          undersigned, thereunto duly authorized.
        Date	February 19,
          2000
        PARACELSIAN, INC.
        By:/s/
          T. COLIN CAMPBELL
          -------------------------------------
          T. Colin Campbell
          President,
          Chief Executive Officer
        By/s/
          GARY G. CHABOT
          ---------------------------------
          Gary G. Chabot
          Principal Accounting
          Officer(Page
          13)
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------